Why is $RVMD moving today? · SEC 8-K archive

$RVMD SEC Filing Alert & Real-Time AI Stock Impact Analysis

T0 SEO archive for $RVMD: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).

← All archive signals

FAQ: $RVMD filing catalyst

Why did $RVMD trigger an AI stock catalyst alert?

$RVMD triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: +3.0/10). Headline: Revolution Medicines Reports Q3 2026: RASONQUE Launches with $198M Revenue, Net Loss Widens to $407.5M. Key points: - RASONQUE (daraxonrasib) generated $198 million in net product revenue during a partial launch quarter following FDA approval - Net loss widened to $407.5 million (-$1.90/share) from $305.2 million in Q3 2025 - Full-year 2026 GAAP operating expense guidance reiterated at $2.1B-$2.2B

How did $RVMD stock react after the SEC filing?

After the SEC 8-K for $RVMD, observed market reaction: T0 price $199.70. Past moves do not guarantee future results.

Where can I get real-time $RVMD SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $RVMD via Telegram and the VIP Web Terminal from €10/month.

$RVMD – Revolution Medicines Reports Q3 2026: RASONQUE Launches with $198M Revenue, Net Loss Widens to $407.5M

Revolution Medicines, Inc.
· SEC 8-K · All $RVMD

Unlocked archive · Analyzed in <2s at T0

Bullish AI Sentiment (+3.0 / 10)
  • RASONQUE (daraxonrasib) generated $198 million in net product revenue during a partial launch quarter following FDA approval
  • Net loss widened to $407.5 million (-$1.90/share) from $305.2 million in Q3 2025
  • Full-year 2026 GAAP operating expense guidance reiterated at $2.1B-$2.2B